Accessibility Menu
Ixico Plc logo

Ixico Plc(OTC) PHYOF

Market Cap$15.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-91%
5 Year-95%
1 Year+0%
1 Month+0%
$0.07
-53.33%
-0.08Today
Ixico Plc last closing stock price
MetricPriceDate
Last closeUSD 0.072025-12-11
Ixico Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.072024-08-01
1 month+0%USD 0.072024-08-01
3 month+0%USD 0.072024-08-01
Year to date+0%USD 0.072024-08-01
1 year+0%USD 0.072024-08-01
3 year-80%USD 0.352022-09-14
5 year-95.25%USD 1.472020-11-23
Since inception-91.36%USD 0.812013-12-03

Ixico Plc Financials at a Glance

Market Cap

$15.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£13.72M

Net Income (TTM)

-£3.37M

EPS (TTM)

-$0.03

P/E Ratio

-2.66

Dividend

$0.00

Beta (Volatility)

3.00 (High)

Price

$0.07

Volume

2

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.07

52-Week Range

$0.07 - $0.07

Estimated Earnings Date

May 18, 2026

PHYOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ixico Plc

IXICO plc is a London-based company specializing in advanced data analytics services for the biopharmaceutical industry. The company focuses on the entire lifecycle of clinical study data, offering innovative solutions for neurological disorders.

Products and Services
  • Proprietary platforms like Assessa for patient selection and TrialTracker for imaging services
  • Comprehensive analytics for drug development and clinical trial support
  • Expert consultancy and project management for clinical studies
Growth Outlook
  • Focus on neurological disorders positions IXICO in a growing market
  • Recent partnerships enhance service offerings and market reach
  • Investment in technology aims to improve operational efficiency
Financial Highlights
  • Recent quarterly revenue of 3.96 million GBP, showing growth potential
  • Gross profit margin of 50.9% indicates strong operational efficiency
  • Current ratio of 2.83 suggests solid liquidity position
IXICO plc operates within the biotechnology sector, providing essential services to the biopharmaceutical industry. The company's focus on neurological disorders, including Alzheimer's and Parkinson's diseases, positions it well in a growing market. With proprietary technologies like Assessa and TrialTracker, IXICO enhances clinical trial efficiency and data management. Recent financial performance shows promising revenue growth and a strong gross profit margin, indicating effective cost management. The company's solid liquidity position further supports its operational capabilities. As IXICO continues to innovate and expand its service offerings, it remains a noteworthy player in the biotechnology landscape.
AI Generated • Jul 17, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Bram Goorden

Website

ixico.com

Headquarters

London, GL EC1A 9PN, GB

PHYOF Financials

Key Financial Metrics (TTM)

Gross Margin

48.26%

Operating Margin

-35.66%

Net Income Margin

-24.98%

Return on Equity

-16.18%

Return on Capital

-21.43%

Return on Assets

-13.99%

Earnings Yield

-37.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

218.97M

Volume

2

Avg. Volume

0

Financials (TTM)

Gross Profit

£6.76M

Operating Income

-£4.89M

EBITDA

-£3.31M

Operating Cash Flow

-£2.81M

Capital Expenditure

-£1.00M

Free Cash Flow

-£3.81M

Cash & ST Invst.

£1.68M

Total Debt

£560.43K

Ixico Plc Performance Analysis

Ixico Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30GBP 11,025,469-12.3%
20232023-09-30GBP 8,160,792-26.0%
20242024-09-30GBP 7,308,083-10.4%
20252025-09-30GBP 8,531,69016.7%
Ixico Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-3027.2%
Q22025-03-31-0.6%
Q42025-09-303.7%
Q22026-03-3119.0%
Ixico Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30GBP 0.03-36.8%
20232023-09-30GBP -0.03N/A
20242024-09-30GBP -0.0575.6%
20252025-09-30GBP -0.02-54.1%
Ixico Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-3058.2%
Q22025-03-319.0%
Q42025-09-3033.3%
Q22026-03-31-63.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£3.96M

+56.0%

Gross Profit

£2.02M

+97.8%

Gross Margin

50.95%

N/A

Market Cap

$15.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$194.03K

N/A

Employees

79

N/A

Net Income

-£1.13M

+20.2%

EBITDA

-£989.52K

+26.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£1.68M

-33.7%

Total Debt

£560.43K

+73.5%

Accounts Receivable

£3.44M

+141.5%

Inventory

£0.00

N/A

Long Term Debt

£450.15K

+116.4%

Short Term Debt

£110.00K

-4.3%

Return on Assets

-13.99%

N/A

Return on Invested Capital

-23.20%

N/A

Free Cash Flow

-£1.39M

-16.3%

Operating Cash Flow

-£1.27M

-8.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDXHFMedX Health Corp
$0.04+0.00%
ZIVOZIVO Bioscience, Inc.
$5.00+0.00%
IUGNFImugene Limited
$0.10+0.00%
BSEMBioStem Technologies, Inc.
$3.82-4.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Questions About PHYOF

What is the current price of Ixico Plc?

Ixico Plc is trading at $0.07 per share.

What is the 52-week range for Ixico Plc?

Over the past 52 weeks, Ixico Plc has traded between $0.07 and $0.07.

How much debt does Ixico Plc have?

As of the most recent reporting period, Ixico Plc reported total debt of £240.98K.

How much cash does Ixico Plc have on hand?

Ixico Plc reported £4.76M in cash and cash equivalents in its most recent financial results.

What is Ixico Plc’s dividend yield?

Ixico Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services